OBJECTIVE: To detect anti-peptidylarginine deiminase 4 (PAD4) antibody in patients with rheumatoid arthritis (RA) and to investigate its clinical significance in the pathogenesis of RA. METHODS: Serum samples were obtained from 109 patients with RA, 67 systemic lupus erythematosus (SLE), 48 primary Sjögren's syndrome (pSS), 41 systemic sclerosis (SSc), 34 osteoarthritis (OA), 23 dermatomyositis/polymyositis (DM/PM), and 19 ankylosing spondylitis (AS) and 106 healthy individuals. The presence of antibodies against recombinant human PAD4 (anti-PAD4) was examined by ELISA. Associations between anti-PAD4 and the clinical features of RA were evaluated. RESULTS: The prevalence of anti-PAD4 in RA patients (45.0%) was significantly higher than those of SLE (9.0%), pSS (4.2%), SSc (9.8%), OA (5.9%), DM/PM (13.0%), AS (0%), and controls (4.7%). The mean titer of anti-PAD4 in RA was also significantly higher than in SLE, other rheumatic diseases, and controls. Disease Activity Score-28 (DAS28), anti-cyclic citrullinated peptide (CCP) antibody, erythrocyte sedimentation rate, rheumatoid factor, IgM, and IgG in anti-PAD4-positive patients were all higher than in anti-PAD4-negative patients. There were positive correlations between anti-PAD4 and DAS28 score (r = 0.333, p < 0.01) and anti-CCP antibody (r = 0.248, p < 0.05). CONCLUSION: The presence of anti-PAD4 in RA indicates that PAD4 may act as an autoantigen that may play a role in the pathogenesis of RA.
OBJECTIVE: To detect anti-peptidylarginine deiminase 4 (PAD4) antibody in patients with rheumatoid arthritis (RA) and to investigate its clinical significance in the pathogenesis of RA. METHODS: Serum samples were obtained from 109 patients with RA, 67 systemic lupus erythematosus (SLE), 48 primary Sjögren's syndrome (pSS), 41 systemic sclerosis (SSc), 34 osteoarthritis (OA), 23 dermatomyositis/polymyositis (DM/PM), and 19 ankylosing spondylitis (AS) and 106 healthy individuals. The presence of antibodies against recombinant humanPAD4 (anti-PAD4) was examined by ELISA. Associations between anti-PAD4 and the clinical features of RA were evaluated. RESULTS: The prevalence of anti-PAD4 in RA patients (45.0%) was significantly higher than those of SLE (9.0%), pSS (4.2%), SSc (9.8%), OA (5.9%), DM/PM (13.0%), AS (0%), and controls (4.7%). The mean titer of anti-PAD4 in RA was also significantly higher than in SLE, other rheumatic diseases, and controls. Disease Activity Score-28 (DAS28), anti-cyclic citrullinated peptide (CCP) antibody, erythrocyte sedimentation rate, rheumatoid factor, IgM, and IgG in anti-PAD4-positive patients were all higher than in anti-PAD4-negative patients. There were positive correlations between anti-PAD4 and DAS28 score (r = 0.333, p < 0.01) and anti-CCP antibody (r = 0.248, p < 0.05). CONCLUSION: The presence of anti-PAD4 in RA indicates that PAD4 may act as an autoantigen that may play a role in the pathogenesis of RA.
Authors: Erika Darrah; Fang Yu; Laura C Cappelli; Antony Rosen; James R O'Dell; Ted R Mikuls Journal: Arthritis Rheumatol Date: 2019-04-10 Impact factor: 10.995
Authors: Z Reyes-Castillo; C A Palafox-Sánchez; I Parra-Rojas; G E Martínez-Bonilla; S del Toro-Arreola; M G Ramírez-Dueñas; G Ocampo-Bermudes; José F Muñoz-Valle Journal: Clin Exp Immunol Date: 2015-09-16 Impact factor: 4.330
Authors: Erika Darrah; Ryan L Davis; Ashley M Curran; Pooja Naik; Ruiqiang Chen; Chan Hyun Na; Jon T Giles; Felipe Andrade Journal: Arthritis Rheumatol Date: 2020-07-14 Impact factor: 10.995
Authors: Elizabeth D Ferucci; Erika Darrah; Irene Smolik; Tammy L Choromanski; David B Robinson; Marianna M Newkirk; Marvin J Fritzler; Antony Rosen; Hani S El-Gabalawy Journal: J Rheumatol Date: 2013-08-01 Impact factor: 4.666